trial

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the successful completion of a Pha...
Read More
en_GBEnglish